Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 9/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 3/20 | 0.38 |
| ▸ | HTR1B | P28222 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16541456 | 0.83 | TP53 (0.44) | WDR5HSD11B1NOTUMHTR1DHTR1B | |
| SCHEMBL17708399 | 0.83 | RBP4 (0.40) | HSD11B1NOTUMSYKPHGDHRBP4 | |
| SCHEMBL26406990 | 0.82 | HSD11B1 (0.40) | WDR5HSD11B1NOTUMHTR1DHTR1B | |
| SCHEMBL24123786 | 0.82 | HSD11B1 (0.40) | WDR5HSD11B1NOTUMHTR1DHTR1B | |
| SCHEMBL24123780 | 0.81 | HTR2C (0.40) | NOTUMSYKPHGDHRBP4 | |
| SCHEMBL20648858 | 0.81 | ACACB (0.39) | WDR5 | |
| SCHEMBL20180602 | 0.80 | ALDH1A1 (0.42) | — | |
| SCHEMBL22765834 | 0.79 | HSD11B1 (0.46) | WDR5HSD11B1HTR1DHTR1BRBP4 | |
| SCHEMBL12017807 | 0.78 | ADRB2 (0.55) | — | |
| SCHEMBL23262620 | 0.78 | HTR1B (0.34) | HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | IMPACT THERAPEUTICS, INC (CN) | 2020-07-07 | — | — | US | disclosed |
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2019-10-10 | — | — | US | disclosed |
| WO-2018090939-A1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | 上海瑛派药业有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | WDR5 317/4885HSD11B1 2836/4885NOTUM 366/4885 |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | WDR5 317/4885HSD11B1 2836/4885NOTUM 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.